Federal Register Notice: FDA’s Anesthetic and Analgesic Drug Products Advisory Committee will meet 11/6, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss an Organon USA Inc. NDA for sugammadex sodium injection for the proposed indication of reversing moderate or deep neuromuscular blockade induced by rocuronium or vecuronium. Contact Stephanie L. Begansky, (301) 796-9001. To view this notice, click here.